SMITHFIELD, N.C. (WTVD) -- New census data found Johnston County is the fastest-growing county in the state in the last 5 ...

Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.

Ziltivekimab is under clinical development by Novo Nordisk and currently in Phase III for Diastolic Heart Failure (HFpEF). According to GlobalData, Phase III drugs for Diastolic Heart Failure (HFpEF) ...

And in Novo Nordisk’s CagriSema trial, 40% of participants did lose at least 25% of their body weight – just not enough to bump the trial’s overall average result past that benchmark.

(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Novo Nordisk ( (NVO)) just unveiled an announcement. Novo Nordisk has announced the successful results of its ...

COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of 2025 that it ...

Novo Nordisk falls most on record after new weight drug disappoints Novo’s shares plunged as much as 27 per cent, and they’re now down 17 per cent for the year after a previous runup on the strength ...

No­vo Nordisk is ex­plor­ing a new class of small mol­e­cule drugs that act as match­mak­ers be­tween two pro­teins in part­ner­ship with a biotech start­up called … ...

This story was updated to add new information. The parent company of Danish drug maker Novo Nordisk said it completed its $16.5 billion purchase of Catalent, including the Bloomington operations ...

Novo Nordisk, for its part, has been working hard to enrich its cardiometabolic pipeline in areas beyond diabetes and obesity, where the company currently dominates the commercial market with its ...